MET and non-small cell lung carcinoma: Studies also reported that miR-200a plays an active tumor-suppressing role in non-small cell lung cancer, and could also inhibit gefitinib resistance and enhance the radio-sensitivity by deactivating the HGF/c-Met pathway (Zhen et al., 2015; Du et al., 2019).